WO2017213597A1 - Breast milk purification method and device for carrying out the same - Google Patents
Breast milk purification method and device for carrying out the same Download PDFInfo
- Publication number
- WO2017213597A1 WO2017213597A1 PCT/TR2016/050171 TR2016050171W WO2017213597A1 WO 2017213597 A1 WO2017213597 A1 WO 2017213597A1 TR 2016050171 W TR2016050171 W TR 2016050171W WO 2017213597 A1 WO2017213597 A1 WO 2017213597A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- milk
- nanosurface
- infuser
- poly
- chemical
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 235000020256 human milk Nutrition 0.000 title claims description 59
- 210000004251 human milk Anatomy 0.000 title description 57
- 238000000746 purification Methods 0.000 title description 2
- 239000000126 substance Substances 0.000 claims abstract description 49
- 235000013336 milk Nutrition 0.000 claims abstract description 45
- 210000004080 milk Anatomy 0.000 claims abstract description 45
- 239000008267 milk Substances 0.000 claims abstract description 44
- 230000008685 targeting Effects 0.000 claims abstract description 10
- -1 polytetrafluoroethylene Polymers 0.000 claims description 23
- 239000011159 matrix material Substances 0.000 claims description 15
- 210000002445 nipple Anatomy 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 10
- 229930182556 Polyacetal Natural products 0.000 claims description 9
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 9
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 9
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 9
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 9
- 229920006324 polyoxymethylene Polymers 0.000 claims description 9
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 9
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 9
- 238000012800 visualization Methods 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 235000013373 food additive Nutrition 0.000 claims description 7
- 239000002778 food additive Substances 0.000 claims description 7
- 229920002554 vinyl polymer Polymers 0.000 claims description 7
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 6
- 108010059881 Lactase Proteins 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 239000002121 nanofiber Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 229920002492 poly(sulfone) Polymers 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 6
- 239000004632 polycaprolactone Substances 0.000 claims description 6
- 239000004633 polyglycolic acid Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 229920002379 silicone rubber Polymers 0.000 claims description 6
- 239000004945 silicone rubber Substances 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000003905 agrochemical Substances 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 244000061176 Nicotiana tabacum Species 0.000 claims description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 239000004964 aerogel Substances 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000000118 hair dye Substances 0.000 claims description 4
- 229920000140 heteropolymer Polymers 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 4
- 239000004816 latex Substances 0.000 claims description 4
- 229920000126 latex Polymers 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 3
- JGRXEBOFWPLEAV-UHFFFAOYSA-N 2-ethylbutyl prop-2-enoate Chemical compound CCC(CC)COC(=O)C=C JGRXEBOFWPLEAV-UHFFFAOYSA-N 0.000 claims description 3
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 3
- 102000012422 Collagen Type I Human genes 0.000 claims description 3
- 108010022452 Collagen Type I Proteins 0.000 claims description 3
- 102000000503 Collagen Type II Human genes 0.000 claims description 3
- 108010041390 Collagen Type II Proteins 0.000 claims description 3
- 239000001828 Gelatine Substances 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 244000043261 Hevea brasiliensis Species 0.000 claims description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 3
- 240000004760 Pimpinella anisum Species 0.000 claims description 3
- 235000012550 Pimpinella anisum Nutrition 0.000 claims description 3
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 240000002657 Thymus vulgaris Species 0.000 claims description 3
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 3
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 3
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 235000017803 cinnamon Nutrition 0.000 claims description 3
- GTBGXKPAKVYEKJ-UHFFFAOYSA-N decyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C(C)=C GTBGXKPAKVYEKJ-UHFFFAOYSA-N 0.000 claims description 3
- FWLDHHJLVGRRHD-UHFFFAOYSA-N decyl prop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C=C FWLDHHJLVGRRHD-UHFFFAOYSA-N 0.000 claims description 3
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920003052 natural elastomer Polymers 0.000 claims description 3
- 229920001194 natural rubber Polymers 0.000 claims description 3
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadecene Natural products CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 229920001713 poly(ethylene-co-vinyl alcohol) Polymers 0.000 claims description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229920000379 polypropylene carbonate Polymers 0.000 claims description 3
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000002020 sage Nutrition 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 239000001585 thymus vulgaris Substances 0.000 claims description 3
- XOALFFJGWSCQEO-UHFFFAOYSA-N tridecyl prop-2-enoate Chemical compound CCCCCCCCCCCCCOC(=O)C=C XOALFFJGWSCQEO-UHFFFAOYSA-N 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 125000005395 methacrylic acid group Chemical class 0.000 claims description 2
- 238000007493 shaping process Methods 0.000 claims description 2
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 108010022355 Fibroins Proteins 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 239000003676 hair preparation Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 230000009931 harmful effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 102100026189 Beta-galactosidase Human genes 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940116108 lactase Drugs 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 229920001897 terpolymer Polymers 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000598 endocrine disruptor Substances 0.000 description 2
- 231100000049 endocrine disruptor Toxicity 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000034972 Sudden Infant Death Diseases 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001749 colloidal lithography Methods 0.000 description 1
- 239000000549 coloured material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- KEROTHRUZYBWCY-UHFFFAOYSA-N tridecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCOC(=O)C(C)=C KEROTHRUZYBWCY-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
- B01J20/28004—Sorbent size or size distribution, e.g. particle size
- B01J20/28007—Sorbent size or size distribution, e.g. particle size with size in the range 1-100 nanometers, e.g. nanosized particles, nanofibers, nanotubes, nanowires or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/49—Materials comprising an indicator, e.g. colour indicator, pH-indicator
Definitions
- the present invention relates to a method and device for separating unwanted chemicals and their metabolites from breast milk. More particularly, the invention pertains to a novel method and device for the elimination of unsafe compounds found in breast milk by using of nanosurfaces comprising antibodies targeting the chemical compounds whereby removal of these compounds from the breast milk is visualized by the user.
- Breastfeeding offers health benefits to mother and child even after toddlerhood.
- These benefits of breastmilk include, for instance decreased risk of sudden infant death syndrome, increased intelligence, decreased likelihood of contracting middle ear infections, cold and flu resistance, a tiny decrease in the risk of childhood leukaemia, lower risk of childhood onset diabetes, decreased risk of asthma and eczema, decreased dental problems, decreased risk of obesity later in life, and a decreased risk of developing psychological disorders, including in adopted children.
- WO 2004/082558 A2 discloses devices and methods for removal of leukocytes from breast milk whereby a filter is attached to the nipple shield or baby bottle nipple at a location permitting removal of leukocytes.
- the filters mentioned therein are noted to be leukocyte depletion filters and leukocyte reduction filters which require liquid to pass through the said filters. In other words, the liquid (i.e. breast milk) is forced to pass through very small openings which require excessive pressure.
- a filter device such as activated carbon and/or a resin that absorbs/adsorbs cations and anions, organic and inorganic toxins, and endocrine disruptors is provided in a nipple shield or within a baby bottle.
- an object of the present invention is providing a novel device and method for the elimination of chemical moieties that are found in the breast milk and are harmful for the baby's health in a selective manner targeting only the harmful chemical compounds.
- Another, object of the present invention is providing a novel device and method which does not necessitate filtering of breast milk through a porous structure such as a filter.
- Another object of the present invention is developing a device and method for removing of harmful chemicals found in the breast milk even in very low amounts (i.e. ng/mL).
- a further object of the present invention is developing a device and method for removing of unwanted chemicals from breast milk specifically targeting chemicals such as pharmaceutical drugs, agrochemicals, food additives and cosmetics.
- Still a further object of the present invention is eliminating shortcomings of prior art with a reliable and consistent device visualizing removal of unwanted chemicals from breast milk.
- a device for removing an unwanted moiety from milk of a mammalian comprises a nanosurface at least a portion of which is combined with at least one antibody targeting said unwanted moiety wherein the antibody is immobilized on the nanosurface and said portion of the nanosurface comprises means for visualizing binding of the chemical or chemical moiety to the antibody.
- the nanosurface may comprise, for instance, a matrix of polymers, nanofibers, silica beads, aerogels or hydrogels suitable for immobilization of an antibody used in the context of the present invention.
- the antibody as a specific capturing molecule, recognize and binds its antigen or ligand. Capturing molecules should be covalently attached to the nanosurface by reacting -COOH with -NH 2 groups on said nanosurface.
- the milk as mentioned herein is preferably human breast milk.
- the means for visualization as mentioned above comprises preferably a labelling material configured to change colour once the unwanted chemical or chemical moiety is bound to the antibody.
- the visualization means may include a coloured material selected from the group of a latex, and nanosized particles of gold, carbon, silver, selenium or platinum to be bound to the antibody. Most preferably the material comprises colloidal gold particles.
- the nanosurface may further comprise lactase and/or an antibacterial agent.
- the antibacterial agent is preferably selected from the group of chitosan, and an oil or extract of a plant selected from anise, thyme, sage, rosemary and cinnamon.
- lactase and/or antibacterial agent may be incorporated into a membrane provided with the visualization means as mentioned above.
- the device according to the present invention can be a receptacle (1) comprising said nanosurface integrally in an inner wall (11) and/or bottom portion (13) thereof.
- the device can be contemplated as an infuser (2) immersible into milk stored in a receptacle (1) whereby the nanosurface as such constitutes the infuser or the nanosurface is provided in an inner volume of the infuser (2).
- the infuser (2) comprises an open end portion (21) and a closed bottom portion (22) such that the milk can be poured from the open end portion (21) so that the milk can be contacting with infuser's inner surface and gradually released into a receptacle (1).
- the infuser (2) is in the form of a bag comprising the nanosurface on its structure or in an inner volume thereof. Still in a further variation, the infuser (2) is of the type a prism or tablet immersible into the milk stored in a receptacle (1). Additionally, the device can be a baby bottle, nipple or nipple shield incorporated with the nanosurface mentioned above. Further, the device can be a filter which can be affixed to a device for feeding an infant.
- the polymers that can be used in the context of the present invention as the nanosurface may be selected from the group consisting of polyvinyl alcohol (PVA), polyacrylic acid (PAA), methacrylic acids, N-butyl acrylate, N-butyl methacrylate, hexyl acrylate, 2- ethylbutyl acrylate, isooctyl acrylate, 2-ethylhexyl acrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl methacrylatepolyethylene (PE), polyurethane (PU), polycaprolactone, polycarbonate, polytetrafluoroethylene (PTFE), polyacetal (PA), polymethylmethacrylate (PMMA), polyethylene glycols, polyethylene terephthalate (PET), silicone rubber (SR), polysulfone (PS), polylactic acid (
- the antibody as mentioned in the foregoing explanations is specific to a chemical or chemical moiety that is excreted in to the milk.
- These chemicals can be selected from antidepressants and antipsychotic drugs, alkaloids, analgesics, immunosuppressant agents, cephalosporins, drugs used for the treatment of respiratory diseases, and metabolites thereof.
- the present invention relates to a method for removing of a chemical from milk of a mammalian comprising bringing into contact the device as mentioned above with the milk before or during feeding of an infant.
- the method may further comprise placing of the device against flow of the milk such as the milk from mother or a milk pump.
- the method may comprise immersion of the device into the milk stored in a receptacle.
- the invention relates to a method for producing the device as mentioned above, comprising the following steps: providing a nanosurface in the form of a matrix,
- the polymer matrix comprising antibodies and means for visualization into a device for feeding an infant, or shaping the matrix as a strainer or infuser for treatment of the milk.
- the antibodies used in the present invention can be monoclonal or polyclonal, or can be obtained from cell lines as conventionally known in the art. Brief Description of the Figures
- Figure 1 is a perspective view of an embodiment according to the present invention wherein the nanosurface is provided in inner wall and/or bottom surface of a receptacle.
- Figure 2 is a perspective view of another embodiment according to the present invention wherein the nanosurface is provided as an infuser device fillable with milk from an open end portion and being immersible into the milk inside of a receptacle.
- Figure 3 is a perspective view of another embodiment according to the present invention wherein the nanosurface is provided as an infuser device in the form of a bag immersible into the milk inside of a receptacle.
- Figure 4 is a perspective view of another embodiment according to the present invention wherein the nanosurface is provided as an infuser device in the form of a prism or tablet immersible into the milk inside of a receptacle.
- the present invention provides a novel method and device which involve use of a nanosurface incorporated with antibodies targeting antigens, namely the unsafe organic and inorganic chemical moieties found in the breast milk.
- the device for separating unwanted compounds from breast milk can be a receptacle such as a baby bottle with or without a nipple, or a breast milk pump comprising said receptacle.
- the device can be a nipple or nipple shield as such, and in this case, the nanosurface incorporated with antibodies can be conveniently placed into these devices so that the breast milk can be treated in situ within the course of feeding an infant.
- the device according the present invention can be formed as an infuser as elaborated in preferred embodiments hereinbelow comprising the nanosurfaces according to the instant invention.
- the nanosurface may comprise, for instance, a matrix of polymers, nanofibers, silica beads, aerogels or hydrogels suitable for immobilization of an antibody used in the context of the present invention.
- These structures provide a large surface and contact area so that the unwanted chemicals can be easily brought into contact with antibodies and separated from the milk.
- the present invention advantageously incorporates means for visualizing the removal state of the unwanted chemical substances to the corresponding antibody so that the user may be confident with removal of these substances from the breast milk.
- This also advantageously ensure that breast milk can be brought into contact with the device for a sufficient time so that the user can recognize removal of the chemical substances properly and then feed the infant with the milk sufficiently treated.
- This is particularly important because the device of the present invention works with the principle of bringing breast milk into contact with the nanosurface loaded with antibodies, and removing the breast milk before being captured in required concentrations may render the milk insufficiently treated.
- Means for visualizing as mentioned herein may involve any method and arrangement conventionally known in the art such as labelling of antibodies so that a colour change can be observed once the antibodies bind to specific antigens.
- ligand-receptor assays available in the art that have been used to detect the presence of various substances in body fluids. These assays involve antigen antibody reactions, synthetic conjugates comprising radioactive, enzymatic, fluorescent, or visually observable metal sol tags, and specially designed reactor chambers.
- a receptor e.g., an antibody, which is specific for the selected ligand or antigen, and a means for detecting the presence, and often the amount, of the ligand- receptor reaction product.
- a rapid detection means including a labelling material such as a latex or nanosized particles of gold, carbon, silver, selenium and platinum.
- a labelling material such as a latex or nanosized particles of gold, carbon, silver, selenium and platinum.
- latex or nanosized particles are conjugated with antibodies and they cause a change in colour once the antibodies are bound with corresponding antigens.
- colloidal gold is particularly preferred.
- the nanosurface used in the device according to the present invention may further comprise lactase for use specifically to treat breast milk for feeding infants lacking lactase.
- This enzyme can be impregnated to or immobilized on the nanosurface.
- the device according to the present invention may further comprise an antibacterial agent.
- the nanosurface of the current invention can therefore become a bactericidal surface which prevents bacterial proliferation. This is particularly advantageous because the device having a bactericidal surface become reusable repeatedly.
- Natural polymers such as chitosan are known to have antibacterial properties, and therefore a nanosurface made of chitosan for use in the context of the present invention would inherently provide antibacterial properties without the need for including further agents.
- an antibacterial agent preferably of natural origin such as the oils or extracts of anise, thyme, sage, rosemary, cinnamon or combinations thereof can be used in the nanosurface of the present invention.
- the nanosurface according to the present invention can be provided within a baby bottle, nipple, nipple shield or any receptacle for the breast milk in any form and location as long as the milky liquid can be brought into contact with the nanosurface containing specific antibodies. It is thus up to the designer to provide suitable embodiments of the invention. However, it would be preferable to provide the nanosurface in an arrangement such that the best possible contact area during the flow or storage of the breast milk can be obtained.
- the nanosurface can be placed over the inner walls (11) and/or bottom surface (12) of a receptacle (1) (e.g. baby bottle) such that nanosurface and antibodies can be brought into contact with breast milk in a simple manner.
- the nanosurface as scrutinized in the foregoing explanations can be contemplated in the form of an infuser (2) as shown in Figs. 2, 3 and 4.
- the infuser (2) shown in Fig. 2 is configured to be placed inside a receptacle (1) from the mouth portion (13) thereof in a manner extending along the inner volume of the receptacle (1) and providing a large contact area with the milk stored therein. It has an open end portion (21) where breast milk can be poured into the inner volume thereof, and a bottom portion (22) which is actually closed.
- this infuser device (2) can be formed in a porous structure (i.e.
- the infuser device (2) may directly be placed into a receptacle (1) which is already filled with breast milk, and in this case, breast milk is moved in the reverse direction, i.e. through the inner volume of the infuser device (2). In both of the usage modes, milk is brought into contact with the nanosurface of the infuser device (2) in an efficient way and unwanted chemicals are removed without exerting an extra effort.
- the infuser device (2) is contemplated as a bag (i.e.
- tea bag shaped comprising a matrix of the nanosurface which is designed for immersion into the breast milk stored in a receptacle (1) as shown in Fig. 3.
- nanosurface may constitute the said infuser device (2) or it can be stored within an inner volume of the same. This arrangement also suggests removal of unwanted chemicals without extra effort because of the antibodies immobilized on the nanosurface catching and entrapping of the corresponding unwanted chemicals or moieties and it can be simply immersed into the breast milk in a receptacle (1).
- Fig. 3 shows a further embodiment as shown in Fig.
- the infuser device (2) can be provided as a rigid prism or tablet which can be immersed into the receptacle (1) from a mouth portion (13) thereof so that it can be readily brought into contact with the milk stored in the receptacle (1). Similar to the infuser device (2) as shown in Fig. 3, this device also comprise a nanosurface and it can be stored within an inner volume of the same.
- the nanosurface containing antibodies can be integrated into a device for feeding an infant, such as baby bottles, nipples, nipple shields or milking pumps, or it can be arranged in a disposable manner such as the infuser devices (2) exemplified in the above mentioned embodiments.
- Providing the nanosurface as a disposable device is advantageous because it suggests simplicity and eliminates the need for regeneration of the nanosurface after treatment of the breast milk.
- nanosurfaces of the present invention can be designed in the form a conventional filter for screening and treating the breast milk in situ.
- the present invention is advantageous in that the need for very smaller openings (i.e.
- the nanosurfaces according to the present invention may comprise, for instance, a matrix of polymers, nanofibers, silica beads, aerogels or hydrogels suitable for immobilization of an antibody.
- These nanosurfaces are well-known in the art, and are known to be advantageous for immobilization of organic molecules such as peptides, enzymes and antibodies because of their high aspect ratio, large surface area to volume ratio, thermal and chemical stability, high porosity, high directional strength, biocompatibility and biodegradability, good structural morphology and flexibility.
- mold copying colloidal lithography, interfacial polymerization, nanoprecipitation, multiple solvent emulsion evaporation, nano-identification, electrospray, self-assembly, drawing, phase separation, and electrospinning methods may be used.
- nanofibers are particularly preferred because they suggest high surface area and are noted to be very suitable for immobilization of antibodies over the surface thereof. This method is also advantageous in obtaining increased porousness and providing antibody /polymer mixture in optimum homogeneity.
- Nanosurfaces forming a matrix for immobilization of antibodies according to this invention can be made of the polymers which are preferably biocompatible and/or biodegradable polymers and they can be of natural and/or synthetic origin. Synthetic polymers may be selected from homopolymers, heteropolymers or copolymers and terpolymers.
- Nanostructures may be formed by use of one or a combination from the group of polyvinyl alcohol (PVA), polyacrylic acid (PAA), polyethylene (PE), polyurethane (PU), polycaprolactone, polycarbonate, polytetrafluoroethylene (PTFE), polyacetal (PA), polymethylmethacrylate (PMMA), polyethylene glycols, polyethylene terephthalate (PET), silicone rubber (SR), polysulfone (PS), polylactic acid (PLA), polyglycolic acid (PGA), poly(DTE carbonate), poly(propylene carbonate), polytetrafluoroethylene, polyacetal, polymethylmethacrylate, polyethylene terephthalate, polycaprolactone, polyvinylpyrrolidone, acrylic polymers, alpha hydroxy acid polyester, beta-l,3-glucan, natural rubber, cellulose, Type-I collagen, Type-II collagen, alginate, gelatine, chitosan, fibrinogen, chitin, elastin
- Heteropolymer or copolymers of the invention can be selected from alternative copolymer, periodic copolymer, statistical copolymer, block copolymer, terpolymer and graft copolymer.
- Acrylic polymers used in the invention are homopolymer, copolymer, terpolymer and acrylic acid-like polymers.
- Polyacrylates may be selected from the group containing acrylic acid, methacrylic acid, N-butyl acrylate, N-butyl methacrylate, hexyl acrylate, 2- ethylbutyl acrylate, isooctyl acrylate, 2-ethylhexyl acrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl methacrylate or mixtures thereof.
- the antibodies used in the context of the present invention can be obtained biologically or by way of synthetic methods as conventionally known in the art.
- a specific antigen is bonded with a hapten and injected to a rabbit for the production of the corresponding antibody which can be isolated from rabbit's blood later on and used with the nanosurfaces of the present invention.
- antibodies can be produced by recombinant techniques.
- antibodies generally are commercially available and they can directly be used depending on the specific chemical moiety targeted in the breast milk.
- the novel device and method of the present invention is noted to be advantageous for elimination of chemicals such as food additives, cosmetics, hair dyes, agrochemicals, sweeteners, tobacco and drugs, or their metabolites from the breast milk even if they exist in trace amounts while providing the user's confidence by visual means.
- chemicals such as food additives, cosmetics, hair dyes, agrochemicals, sweeteners, tobacco and drugs, or their metabolites from the breast milk even if they exist in trace amounts while providing the user's confidence by visual means.
- Various drugs have already been reported to be excreted to breast milk easily and being harmful for the infant. The same holds also various metabolites of tobacco and tobacco products.
- the present invention ensures elimination of these and other factors harmful for the health of the infant, and therefore the invention is useful for removing any kind of antigen with high efficiency even if the antigen itself exists in very low amounts in the breast milk, thanks to the antibodies immobilized on a nanosurface. This eliminates conventional techniques relying on screening based on molecule size
- the present invention is particularly suitable for removing unwanted drugs and drug metabolites such as antidepressant and antipsychotic drugs, analgesics, alkaloids, immunosuppressant agents, antibiotics, as well as the drugs widely used in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma from breast milk.
- unwanted drugs and drug metabolites such as antidepressant and antipsychotic drugs, analgesics, alkaloids, immunosuppressant agents, antibiotics, as well as the drugs widely used in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma from breast milk.
- COPD chronic obstructive pulmonary disease
- the means for visualizing removal of the unwanted chemicals advantageously ensures user's confidence and provides also an indication for the user about waiting time necessary for completing the reactions between the chemical substances and antibodies.
Abstract
The present invention relates to a method and device for separating unwanted moieties from milk of a mammalian by using of a nanosurface at least a portion of which is combined with at least one antibody targeting said chemical moiety. The nanosurface further comprises means for visualizing binding of the unwanted chemical or chemical moiety to the antibody for the sake of providing user's confidence and proper usage of the device according to the present invention.
Description
BREAST MILK PURIFICATION METHOD AND DEVICE FOR CARRYING OUT THE
SAME Technical Field of the Invention
The present invention relates to a method and device for separating unwanted chemicals and their metabolites from breast milk. More particularly, the invention pertains to a novel method and device for the elimination of unsafe compounds found in breast milk by using of nanosurfaces comprising antibodies targeting the chemical compounds whereby removal of these compounds from the breast milk is visualized by the user.
Background of the Invention
Milk is the primary source of nutrition for newborns before they are able to eat and digest other foods. An infant is generally needed to be fed with breast milk at least for 6 months but supplemented breastfeeding is recommended until at least age two and then for as long as the mother and child wish. The benefits of the breast milk for an infant is well established. Breastfeeding offers health benefits to mother and child even after toddlerhood. These benefits of breastmilk include, for instance decreased risk of sudden infant death syndrome, increased intelligence, decreased likelihood of contracting middle ear infections, cold and flu resistance, a tiny decrease in the risk of childhood leukaemia, lower risk of childhood onset diabetes, decreased risk of asthma and eczema, decreased dental problems, decreased risk of obesity later in life, and a decreased risk of developing psychological disorders, including in adopted children.
However, during the term of the breastfeeding, the mother can be taking consciously or unconsciously various chemicals that can be harmful for the health of the infant. Especially, various factors such as food additives, cosmetics, hair dyes, agrochemicals, sweeteners, tobacco, alcohol and drugs are known to be transmitted to breast milk and threatening infant's health (Ito S, Lee A. Drug excretion into breast milk— Overview Advanced Drug Delivery Reviews 55(5); 617-627, 2003).
If the mother is medicated continuously because of a chronic disease such as diabetes, nephropathy or cardiac diseases, breastfeeding may not be recommended and therefore the infant is fed with baby foods being deprived of the benefits obtainable with breast milk. The concentration of most drugs in the breast milk is close to their concentration in maternal plasma (Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med 10:149-159, 2005). Mothers receiving beta-blockers, salicylates, lithium and antineoplastic agents are generally not allowed for breastfeeding of infants younger than 6 months. Particularly, there are various problems reported so far in nerve transmission of the infants fed with breast milk of mothers receiving antidepressant agents (Sagraves R. Drugs in Breast Milk: a Scientific Explanation. J Pediatr Health Care. 11(5): 230-235,1997). It is also shown that nicotine and its metabolite cotinine transmitted to the baby through the breast milk and has adverse effects as well (Bogen DL, Davies ED, Barnhart WC, Lucero CA, Moss DR. What do mothers think about concurrent breast-feeding and smoking? Ambul Pediatr. 8(3):200-204, 2008; Mennella JA, Yourshaw LM, Morgan LK. Breastfeeding and smoking: short-term effects on infant feeding and sleep. Pediatrics. 120(3):497-502, 2007). Additionally, cosmetics, hair dyes, sweeteners, food additives, preservatives and agrochemicals with continuous uptake in daily life are reported to be excreting to the breast milk and causing various health problems like autism, hyperactivity and cancer in the infant (Hill HJ. Food additives and contaminants and their contribution to the human cancer load. Eur J Cancer Prev 2:291-295, 1993, Pollock I. Hyperactivity and food additives. Bibl Nutr Dieta 48:81-89, 1991).
It is therefore, desirable to separate these harmful chemical compounds from the breast milk before breastfeeding the infant. There have been various attempts for filtering and removing of undesired components of the breast milk for preventing harmful effects thereof on the newborn infants. WO 2004/082558 A2, for instance discloses devices and methods for removal of leukocytes from breast milk whereby a filter is attached to the nipple shield or baby bottle nipple at a location permitting removal of leukocytes. The filters mentioned therein are noted to be leukocyte depletion filters and leukocyte reduction filters which require liquid to pass through the said filters. In other words, the liquid (i.e. breast milk) is forced to pass through very small openings which require excessive pressure. Another device for removing organic/inorganic toxins such as halogenated endocrine disruptors, heavy metals and radionuclides is disclosed in US
2007/0005006 Al. Accordingly, a filter device such as activated carbon and/or a resin that absorbs/adsorbs cations and anions, organic and inorganic toxins, and endocrine disruptors is provided in a nipple shield or within a baby bottle. These arrangements have the very strict requirement of screening the milk through the pores having very small openings, and filtering therefore is carried out according to the particle size of the unwanted moiety. Very small pore openings would readily be noted as disadvantageous as they can fail in screening of toxic moieties or they can be screening the beneficial ingredients of the breast milk besides the toxic moieties. Therefore, it is quite hard with the conventional devices targeting solely of the undesired toxic moieties with high precision and efficiency, and also without drawbacks such as high pressure gradients and complicated system requirements.
It is also important to visualize removal of the unwanted chemical moieties by the user. The user needs to be assured of whether the moieties have been properly removed from the breast milk for the sake of providing user's confidence and proper usage of a removal system.
Accordingly, an object of the present invention is providing a novel device and method for the elimination of chemical moieties that are found in the breast milk and are harmful for the baby's health in a selective manner targeting only the harmful chemical compounds.
Another, object of the present invention is providing a novel device and method which does not necessitate filtering of breast milk through a porous structure such as a filter.
Another object of the present invention is developing a device and method for removing of harmful chemicals found in the breast milk even in very low amounts (i.e. ng/mL). A further object of the present invention is developing a device and method for removing of unwanted chemicals from breast milk specifically targeting chemicals such as pharmaceutical drugs, agrochemicals, food additives and cosmetics.
Still a further object of the present invention is eliminating shortcomings of prior art with a reliable and consistent device visualizing removal of unwanted chemicals from breast milk.
Further objects and advantages of the present invention will be apparent from the description below. These and other objectives of the present invention are attained with a novel device and method according to the appended claims. Brief Description of the Invention
In an aspect of the present invention, a device for removing an unwanted moiety from milk of a mammalian is provided. The device comprises a nanosurface at least a portion of which is combined with at least one antibody targeting said unwanted moiety wherein the antibody is immobilized on the nanosurface and said portion of the nanosurface comprises means for visualizing binding of the chemical or chemical moiety to the antibody. The nanosurface may comprise, for instance, a matrix of polymers, nanofibers, silica beads, aerogels or hydrogels suitable for immobilization of an antibody used in the context of the present invention. The antibody, as a specific capturing molecule, recognize and binds its antigen or ligand. Capturing molecules should be covalently attached to the nanosurface by reacting -COOH with -NH2 groups on said nanosurface. The milk as mentioned herein is preferably human breast milk.
The means for visualization as mentioned above comprises preferably a labelling material configured to change colour once the unwanted chemical or chemical moiety is bound to the antibody. More particularly the visualization means may include a coloured material selected from the group of a latex, and nanosized particles of gold, carbon, silver, selenium or platinum to be bound to the antibody. Most preferably the material comprises colloidal gold particles. In another aspect the nanosurface may further comprise lactase and/or an antibacterial agent. The antibacterial agent is preferably selected from the group of chitosan, and an oil or extract of a plant selected from anise, thyme, sage, rosemary and cinnamon. In this
aspect, lactase and/or antibacterial agent may be incorporated into a membrane provided with the visualization means as mentioned above.
The device according to the present invention can be a receptacle (1) comprising said nanosurface integrally in an inner wall (11) and/or bottom portion (13) thereof. Alternatively the device can be contemplated as an infuser (2) immersible into milk stored in a receptacle (1) whereby the nanosurface as such constitutes the infuser or the nanosurface is provided in an inner volume of the infuser (2). In a variation, the infuser (2) comprises an open end portion (21) and a closed bottom portion (22) such that the milk can be poured from the open end portion (21) so that the milk can be contacting with infuser's inner surface and gradually released into a receptacle (1). In another variation, the infuser (2) is in the form of a bag comprising the nanosurface on its structure or in an inner volume thereof. Still in a further variation, the infuser (2) is of the type a prism or tablet immersible into the milk stored in a receptacle (1). Additionally, the device can be a baby bottle, nipple or nipple shield incorporated with the nanosurface mentioned above. Further, the device can be a filter which can be affixed to a device for feeding an infant.
The polymers that can be used in the context of the present invention as the nanosurface may be selected from the group consisting of polyvinyl alcohol (PVA), polyacrylic acid (PAA), methacrylic acids, N-butyl acrylate, N-butyl methacrylate, hexyl acrylate, 2- ethylbutyl acrylate, isooctyl acrylate, 2-ethylhexyl acrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl methacrylatepolyethylene (PE), polyurethane (PU), polycaprolactone, polycarbonate, polytetrafluoroethylene (PTFE), polyacetal (PA), polymethylmethacrylate (PMMA), polyethylene glycols, polyethylene terephthalate (PET), silicone rubber (SR), polysulfone (PS), polylactic acid (PLA), polyglycolic acid (PGA), poly(DTE carbonate), poly(propylene carbonate), polytetrafluoroethylene, polyacetal, polymethyl methacrylate, polyethylene terephthalate, polycaprolactone, polyvinylpyrrolidone, acrylic polymers, alpha hydroxy acid polyester, beta-l,3-glucan, natural rubber, cellulose, Type-I collagen, Type-II collagen, alginate, gelatine, chitosan; heteropolymer or copolymers including poly(lactic-co-glycolic acid), poly(ethylene glycol-co-lactide), poly(L-lactide-co-e-caprolactone), poly(ethylene-co-vinyl alcohol), styrene-divinyl
benzene copolymer, polyfvinyl chlorite-co-vinyl acetate-co-vinyl alcohol), polyfethylene -alt-maleic anhydride, polypropylene-graft-maleic anhydride), Polyethylene-graft- maleic anhydride, polyfmaleic anhydride-alt- 1-octadecene), polyfisobutylene-alt-maleic anhydride), polystyrene-block-poly(ethylene-ran-butylene)-block-polystyrene-graft- maleic anhydride and polyvinyl alcohol-polyacrylic acid.
The antibody as mentioned in the foregoing explanations is specific to a chemical or chemical moiety that is excreted in to the milk. These chemicals can be selected from antidepressants and antipsychotic drugs, alkaloids, analgesics, immunosuppressant agents, cephalosporins, drugs used for the treatment of respiratory diseases, and metabolites thereof.
In another aspect, the present invention relates to a method for removing of a chemical from milk of a mammalian comprising bringing into contact the device as mentioned above with the milk before or during feeding of an infant. The method may further comprise placing of the device against flow of the milk such as the milk from mother or a milk pump. Alternatively, the method may comprise immersion of the device into the milk stored in a receptacle. In a further aspect, the invention relates to a method for producing the device as mentioned above, comprising the following steps: providing a nanosurface in the form of a matrix,
immobilizing antibodies on the matrix targeting predetermined chemicals or chemical moieties in the milk,
incorporating means for visualization into the matrix, and
placing the polymer matrix comprising antibodies and means for visualization into a device for feeding an infant, or shaping the matrix as a strainer or infuser for treatment of the milk. Furthermore, the antibodies used in the present invention can be monoclonal or polyclonal, or can be obtained from cell lines as conventionally known in the art.
Brief Description of the Figures
Figure 1 is a perspective view of an embodiment according to the present invention wherein the nanosurface is provided in inner wall and/or bottom surface of a receptacle. Figure 2 is a perspective view of another embodiment according to the present invention wherein the nanosurface is provided as an infuser device fillable with milk from an open end portion and being immersible into the milk inside of a receptacle.
Figure 3 is a perspective view of another embodiment according to the present invention wherein the nanosurface is provided as an infuser device in the form of a bag immersible into the milk inside of a receptacle.
Figure 4 is a perspective view of another embodiment according to the present invention wherein the nanosurface is provided as an infuser device in the form of a prism or tablet immersible into the milk inside of a receptacle.
Detailed Description of the Invention
The present invention provides a novel method and device which involve use of a nanosurface incorporated with antibodies targeting antigens, namely the unsafe organic and inorganic chemical moieties found in the breast milk. The device for separating unwanted compounds from breast milk can be a receptacle such as a baby bottle with or without a nipple, or a breast milk pump comprising said receptacle. Alternatively, the device can be a nipple or nipple shield as such, and in this case, the nanosurface incorporated with antibodies can be conveniently placed into these devices so that the breast milk can be treated in situ within the course of feeding an infant. Further, the device according the present invention can be formed as an infuser as elaborated in preferred embodiments hereinbelow comprising the nanosurfaces according to the instant invention. The nanosurface may comprise, for instance, a matrix of polymers, nanofibers, silica beads, aerogels or hydrogels suitable for immobilization of an antibody used in the context of the present invention. These structures provide a large surface and contact area so that the unwanted chemicals can be easily brought into contact with antibodies and separated from the milk.
The present invention advantageously incorporates means for visualizing the removal state of the unwanted chemical substances to the corresponding antibody so that the user may be confident with removal of these substances from the breast milk. This also advantageously ensure that breast milk can be brought into contact with the device for a sufficient time so that the user can recognize removal of the chemical substances properly and then feed the infant with the milk sufficiently treated. This is particularly important because the device of the present invention works with the principle of bringing breast milk into contact with the nanosurface loaded with antibodies, and removing the breast milk before being captured in required concentrations may render the milk insufficiently treated.
Means for visualizing as mentioned herein may involve any method and arrangement conventionally known in the art such as labelling of antibodies so that a colour change can be observed once the antibodies bind to specific antigens. In fact, there are many types of ligand-receptor assays available in the art that have been used to detect the presence of various substances in body fluids. These assays involve antigen antibody reactions, synthetic conjugates comprising radioactive, enzymatic, fluorescent, or visually observable metal sol tags, and specially designed reactor chambers. In all these assays, there is a receptor, e.g., an antibody, which is specific for the selected ligand or antigen, and a means for detecting the presence, and often the amount, of the ligand- receptor reaction product. In the context of the present invention, however, it is preferred to employ a rapid detection means including a labelling material such as a latex or nanosized particles of gold, carbon, silver, selenium and platinum. In this context, latex or nanosized particles are conjugated with antibodies and they cause a change in colour once the antibodies are bound with corresponding antigens. In order to improve sensitivity of the means for visualization according to the current invention, colloidal gold is particularly preferred.
Breast milk, just like the other milks contains lactose, and it is known that a person lacking lactase may experience symptoms of lactose intolerance. This may cause serious health problems in infants fed with breast milk. Therefore, the nanosurface used in the device according to the present invention may further comprise lactase for use
specifically to treat breast milk for feeding infants lacking lactase. This enzyme can be impregnated to or immobilized on the nanosurface.
In another aspect, the device according to the present invention may further comprise an antibacterial agent. The nanosurface of the current invention can therefore become a bactericidal surface which prevents bacterial proliferation. This is particularly advantageous because the device having a bactericidal surface become reusable repeatedly. Natural polymers such as chitosan are known to have antibacterial properties, and therefore a nanosurface made of chitosan for use in the context of the present invention would inherently provide antibacterial properties without the need for including further agents. Alternatively, an antibacterial agent preferably of natural origin such as the oils or extracts of anise, thyme, sage, rosemary, cinnamon or combinations thereof can be used in the nanosurface of the present invention.
Since the antibodies contained in the nanosurface mentioned above readily react with the antigens, structural limitations of the conventional filtering devices, such as the necessity of screening through a filter, are completely eliminated. Therefore, the nanosurface according to the present invention can be provided within a baby bottle, nipple, nipple shield or any receptacle for the breast milk in any form and location as long as the milky liquid can be brought into contact with the nanosurface containing specific antibodies. It is thus up to the designer to provide suitable embodiments of the invention. However, it would be preferable to provide the nanosurface in an arrangement such that the best possible contact area during the flow or storage of the breast milk can be obtained. For instance, in a nipple shield or baby bottle used for immediate feeding of the infant, providing nanosurfaces perpendicular to the direction of milk flow would be preferred because this design would increase retention time in contact area of the milk on the surface, and this would increase also efficiency of removing unwanted compounds from the liquid composition of the breast milk. In a receptacle used for the storage of the breast milk, however a different design can be contemplated where a simple contact of the nanosurface and breast milk would be sufficient. In a preferred embodiment as shown in Fig. 1, for instance, the nanosurface can be placed over the inner walls (11) and/or bottom surface (12) of a receptacle (1)
(e.g. baby bottle) such that nanosurface and antibodies can be brought into contact with breast milk in a simple manner.
In another embodiment of the present invention, the nanosurface as scrutinized in the foregoing explanations can be contemplated in the form of an infuser (2) as shown in Figs. 2, 3 and 4. The infuser (2) shown in Fig. 2 is configured to be placed inside a receptacle (1) from the mouth portion (13) thereof in a manner extending along the inner volume of the receptacle (1) and providing a large contact area with the milk stored therein. It has an open end portion (21) where breast milk can be poured into the inner volume thereof, and a bottom portion (22) which is actually closed. As can be appreciated by a person skilled in the art, this infuser device (2) can be formed in a porous structure (i.e. mesh) such that milk can be retained in its inner volume for a while until it passes through its porous structure to the inner volume of the receptacle (1). Of course, the infuser device (2) may directly be placed into a receptacle (1) which is already filled with breast milk, and in this case, breast milk is moved in the reverse direction, i.e. through the inner volume of the infuser device (2). In both of the usage modes, milk is brought into contact with the nanosurface of the infuser device (2) in an efficient way and unwanted chemicals are removed without exerting an extra effort. In another embodiment of the present invention, the infuser device (2) is contemplated as a bag (i.e. tea bag shaped) comprising a matrix of the nanosurface which is designed for immersion into the breast milk stored in a receptacle (1) as shown in Fig. 3. As can be appreciated by those skilled in the art, nanosurface may constitute the said infuser device (2) or it can be stored within an inner volume of the same. This arrangement also suggests removal of unwanted chemicals without extra effort because of the antibodies immobilized on the nanosurface catching and entrapping of the corresponding unwanted chemicals or moieties and it can be simply immersed into the breast milk in a receptacle (1). In a further embodiment as shown in Fig. 4, the infuser device (2) can be provided as a rigid prism or tablet which can be immersed into the receptacle (1) from a mouth portion (13) thereof so that it can be readily brought into contact with the milk stored in
the receptacle (1). Similar to the infuser device (2) as shown in Fig. 3, this device also comprise a nanosurface and it can be stored within an inner volume of the same.
As noted in the foregoing embodiments, the nanosurface containing antibodies can be integrated into a device for feeding an infant, such as baby bottles, nipples, nipple shields or milking pumps, or it can be arranged in a disposable manner such as the infuser devices (2) exemplified in the above mentioned embodiments. Providing the nanosurface as a disposable device is advantageous because it suggests simplicity and eliminates the need for regeneration of the nanosurface after treatment of the breast milk. Whilst it is not necessary to screen the breast milk, nanosurfaces of the present invention can be designed in the form a conventional filter for screening and treating the breast milk in situ. However, the present invention is advantageous in that the need for very smaller openings (i.e. pores) in a filter is completely eliminated and no physical separation according to the molecule size is needed. Antibodies contained in the nanosurface allow the designer to use larger openings in a filter because the said antibodies attract and catch the antigens once they get into close proximity with the nanosurface.
The nanosurfaces according to the present invention may comprise, for instance, a matrix of polymers, nanofibers, silica beads, aerogels or hydrogels suitable for immobilization of an antibody. These nanosurfaces are well-known in the art, and are known to be advantageous for immobilization of organic molecules such as peptides, enzymes and antibodies because of their high aspect ratio, large surface area to volume ratio, thermal and chemical stability, high porosity, high directional strength, biocompatibility and biodegradability, good structural morphology and flexibility. In order to obtain the polymer in nano structure, mold copying, colloidal lithography, interfacial polymerization, nanoprecipitation, multiple solvent emulsion evaporation, nano-identification, electrospray, self-assembly, drawing, phase separation, and electrospinning methods may be used.
In the context of the present invention, nanofibers are particularly preferred because they suggest high surface area and are noted to be very suitable for immobilization of antibodies over the surface thereof. This method is also advantageous in obtaining
increased porousness and providing antibody /polymer mixture in optimum homogeneity.
Nanosurfaces forming a matrix for immobilization of antibodies according to this invention can be made of the polymers which are preferably biocompatible and/or biodegradable polymers and they can be of natural and/or synthetic origin. Synthetic polymers may be selected from homopolymers, heteropolymers or copolymers and terpolymers. Nanostructures may be formed by use of one or a combination from the group of polyvinyl alcohol (PVA), polyacrylic acid (PAA), polyethylene (PE), polyurethane (PU), polycaprolactone, polycarbonate, polytetrafluoroethylene (PTFE), polyacetal (PA), polymethylmethacrylate (PMMA), polyethylene glycols, polyethylene terephthalate (PET), silicone rubber (SR), polysulfone (PS), polylactic acid (PLA), polyglycolic acid (PGA), poly(DTE carbonate), poly(propylene carbonate), polytetrafluoroethylene, polyacetal, polymethylmethacrylate, polyethylene terephthalate, polycaprolactone, polyvinylpyrrolidone, acrylic polymers, alpha hydroxy acid polyester, beta-l,3-glucan, natural rubber, cellulose, Type-I collagen, Type-II collagen, alginate, gelatine, chitosan, fibrinogen, chitin, elastin, hydroxylapatite, dextran, laminin, hyaluronic acid, starch, silk and similar synthetic or natural biopolymers and/or as a combination of natural/synthetic biopolymers.
Heteropolymer or copolymers of the invention can be selected from alternative copolymer, periodic copolymer, statistical copolymer, block copolymer, terpolymer and graft copolymer. For instance; poly(lactic-co-glycolic acid), poly(ethylene glycol-co- lactide), poly(L-lactide-co-e-caprolactone), poly(ethylene-co-vinyl alcohol), styrene- divinylbenzene copolymer, poly(vinyl chlorite-co-vinyl acetate-co-vinyl alcohol), poly(ethylene-alt-maleic anhydride, polypropylene-graft-maleic anhydride), Polyethylene-graft-maleic anhydride, poly(maleic anhydride-alt- 1-octadecene), poly(isobutylene-alt-maleic anhydride), polystyrene-block-poly(ethylene-ran-butylene)- block-polystyrene-graft-maleic anhydride and polyvinyl alcohol-polyacrylic acid are preferred.
Acrylic polymers used in the invention are homopolymer, copolymer, terpolymer and acrylic acid-like polymers. Polyacrylates may be selected from the group containing
acrylic acid, methacrylic acid, N-butyl acrylate, N-butyl methacrylate, hexyl acrylate, 2- ethylbutyl acrylate, isooctyl acrylate, 2-ethylhexyl acrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl methacrylate or mixtures thereof.
The antibodies used in the context of the present invention can be obtained biologically or by way of synthetic methods as conventionally known in the art. In a typical biological method, for instance, a specific antigen is bonded with a hapten and injected to a rabbit for the production of the corresponding antibody which can be isolated from rabbit's blood later on and used with the nanosurfaces of the present invention. Alternatively, antibodies can be produced by recombinant techniques. However, antibodies generally are commercially available and they can directly be used depending on the specific chemical moiety targeted in the breast milk. The novel device and method of the present invention is noted to be advantageous for elimination of chemicals such as food additives, cosmetics, hair dyes, agrochemicals, sweeteners, tobacco and drugs, or their metabolites from the breast milk even if they exist in trace amounts while providing the user's confidence by visual means. Various drugs have already been reported to be excreted to breast milk easily and being harmful for the infant. The same holds also various metabolites of tobacco and tobacco products. The present invention ensures elimination of these and other factors harmful for the health of the infant, and therefore the invention is useful for removing any kind of antigen with high efficiency even if the antigen itself exists in very low amounts in the breast milk, thanks to the antibodies immobilized on a nanosurface. This eliminates conventional techniques relying on screening based on molecule size of the antigen.
The present invention is particularly suitable for removing unwanted drugs and drug metabolites such as antidepressant and antipsychotic drugs, analgesics, alkaloids, immunosuppressant agents, antibiotics, as well as the drugs widely used in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma from breast milk. The means for visualizing removal of the unwanted chemicals advantageously ensures user's confidence and provides also an indication for the user about waiting time necessary for completing the reactions between the chemical substances and antibodies.
Claims
1. A device for separating an unwanted chemical or chemical moiety from milk of a mammalian comprising a nanosurface at least a portion of which is combined with at least one antibody targeting said chemical or chemical moiety wherein said portion of the nanosurface comprises means for visualizing binding of the unwanted chemical or chemical moiety to the antibody.
2. A device according to claim 1 wherein the milk is human breast milk.
3. A device according to claim 1 wherein the means for visualization comprises a labelling material configured to change colour once the unwanted chemical or chemical moiety is bound to the antibody.
4. A device according to claim 3 wherein the labelling material is selected from the group of a latex, and nanosized particles of gold, carbon, silver, selenium or platinum.
5. A device according to claim 4 wherein the labelling material is a colloidal gold.
6. A device according to claim 1 wherein the nanosurface further comprises lactase enzyme.
7. A device according to claim 1 wherein the nanosurface further comprises an antibacterial agent.
8. A device according to claim 7 wherein the antibacterial agent is selected from the group of chitosan, and an oil or extract of a plant selected from anise, thyme, sage, rosemary and cinnamon.
9. A device according to claim 1 wherein the device is a receptacle (1) comprising said nanosurface integrally in an inner wall (11) and/or bottom portion (13) thereof.
10. A device according to claim 1 wherein the device is an infuser (2) immersible into milk stored in a receptacle (1) whereby the nanosurface as such constitutes the infuser (2) or the nanosurface is provided in an inner volume of the infuser (2).
11. A device according to claim 10 wherein the infuser (2) comprises an open end portion (21) and a closed bottom portion (22) such that the milk can be poured from the open end portion (21) so that milk can be contacting with infuser's inner surface and gradually released into a receptacle (1).
12. A device according to claim 10 wherein the infuser (2) is in the form of a bag comprising the nanosurface on its surface or in an inner volume thereof.
13. A device according to claim 10 wherein the infuser (2) is of the type a prism or tablet immersible into the milk stored in a receptacle (1).
14. A device according to claim 1 wherein the device is a baby bottle, nipple or nipple shield incorporated with the nanosurface.
15. A device according to claim 1 wherein the device is a strainer which can be affixed to a device for feeding an infant.
16. A device according to claim 1 wherein the nanosurface is in the form of polymer nanofibers, silica or polymer beads, aerogels or hydrogels having an adsorbent surface for the antibody.
17. A device according to claim 16 wherein the polymer forming the nanofibers is selected from the group consisting of polyvinyl alcohol (PVA), polyacrylic acid (PAA), methacrylic acids, N-butyl acrylate, N-butyl methacrylate, hexyl acrylate, 2- ethylbutyl acrylate, isooctyl acrylate, 2-ethylhexyl acrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl methacrylatepolyethylene (PE), polyurethane (PU)< polycaprolactone, polycarbonate, polytetrafluoroethylene (PTFE), polyacetal (PA), polymethylmethacrylate (PMMA), polyethylene glycols, polyethylene terephthalate (PET), silicone rubber (SR), polysulfone (PS), polylactic acid (PLA), polyglycolic acid (PGA), poly(DTE carbonate), poly(propylene carbonate),
polytetrafluoroethylene, polyacetal, polymethylmethacrylate, polyethylene terephthalate, polycaprolactone, polyvinylpyrrolidone, acrylic polymers, alpha hydroxy acid polyester, beta-l,3-glucan, natural rubber, cellulose, Type-I collagen, Type-II collagen, alginate, gelatine, silk, fibroin, chitosan; heteropolymer or copolymers including poly(lactic-co-glycolic acid), polyfethylene glycol-co-lactide), poly(L-lactide-co-e-caprolactone), poly(ethylene-co-vinyl alcohol), styrene- divinylbenzene copolymer, polyfvinyl chlorite-co-vinyl acetate-co-vinyl alcohol), poly(ethylene-alt-maleic anhydride, polypropylene-graft-maleic anhydride), Polyethylene-graft-maleic anhydride, polyfmaleic anhydride-alt- 1-octadecene), poly(isobutylene-alt-maleic anhydride), polystyrene-block-poly(ethylene-ran- butylene)-block-polystyrene-graft-maleic anhydride and polyvinyl alcohol- polyacrylic acid.
18. A device according to claim 1 wherein the antibody is specific to a chemical substrate in the milk selected from natural and synthetic drugs, tobacco and its metabolites, food additives, agrochemicals, sweeteners, hair dyes, and cosmetics.
19. A method for separating an unwanted chemical or chemical moiety from milk of a mammalian comprising bringing into contact the device according to claim 1 with the milk before or during feeding of an infant.
20. A method according to claim 19 wherein the method comprises placing of the device against flow of the milk.
21. A method according to claim 19 wherein the method comprises immersion of the device into the milk stored in a receptacle.
22 A method for producing a device according to claim 1 comprising the steps of: providing a nanosurface in the form of a matrix,
immobilizing antibodies on the matrix targeting unwanted chemicals or chemical moieties in the milk,
incorporating means for visualization into the matrix, and
placing the matrix comprising antibodies and means for visualization into a device for feeding an infant, or shaping the matrix as a strainer or infuser for treatment of the milk.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2016/050171 WO2017213597A1 (en) | 2016-06-08 | 2016-06-08 | Breast milk purification method and device for carrying out the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2016/050171 WO2017213597A1 (en) | 2016-06-08 | 2016-06-08 | Breast milk purification method and device for carrying out the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017213597A1 true WO2017213597A1 (en) | 2017-12-14 |
Family
ID=56360461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2016/050171 WO2017213597A1 (en) | 2016-06-08 | 2016-06-08 | Breast milk purification method and device for carrying out the same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017213597A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109126887A (en) * | 2018-09-10 | 2019-01-04 | 湖南科技大学 | A kind of preparation method of polyurethane composite photocatalysis membrane |
WO2019126308A1 (en) * | 2017-12-19 | 2019-06-27 | Stc.Unm | Lipase inhibitors to prevent rancidity in expressed human milk during storage |
CN110835458A (en) * | 2019-11-15 | 2020-02-25 | 湖南绿斯达生物科技有限公司 | Biodegradable material with antibacterial effect and high strength, and preparation and application thereof |
CN110975834A (en) * | 2019-12-19 | 2020-04-10 | 浙江工业大学 | Ultra-light floatable material and preparation method and application thereof |
US11771769B2 (en) | 2017-11-10 | 2023-10-03 | Cocoon Biotech Inc. | Ocular applications of silk-based products |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032571A1 (en) * | 1996-03-06 | 1997-09-12 | Hyperion Catalysis International, Inc. | Functionalized nanotubes |
US20030088192A1 (en) * | 2001-11-06 | 2003-05-08 | Thomas Lengsfeld | Test system for studying a biological fluid |
WO2004082558A2 (en) | 2003-03-14 | 2004-09-30 | New York University | Devices and methods for removal of leukocytes from breast milk |
US20060159916A1 (en) * | 2003-05-05 | 2006-07-20 | Nanosys, Inc. | Nanofiber surfaces for use in enhanced surface area applications |
US20070005006A1 (en) | 2005-06-15 | 2007-01-04 | Rosenfeld Paul E | Methods and devices for removal of toxic compounds from breast milk |
WO2008035888A1 (en) * | 2006-09-21 | 2008-03-27 | Se Hee Kim | Filter device of nursing bottle containing powdered milk, filter device using magnet and feeder |
WO2009009188A2 (en) * | 2007-04-19 | 2009-01-15 | 3M Innovative Properties Company | Uses of water-dispersible silica nanoparticles for attaching biomolecules |
-
2016
- 2016-06-08 WO PCT/TR2016/050171 patent/WO2017213597A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032571A1 (en) * | 1996-03-06 | 1997-09-12 | Hyperion Catalysis International, Inc. | Functionalized nanotubes |
US20030088192A1 (en) * | 2001-11-06 | 2003-05-08 | Thomas Lengsfeld | Test system for studying a biological fluid |
WO2004082558A2 (en) | 2003-03-14 | 2004-09-30 | New York University | Devices and methods for removal of leukocytes from breast milk |
US20060159916A1 (en) * | 2003-05-05 | 2006-07-20 | Nanosys, Inc. | Nanofiber surfaces for use in enhanced surface area applications |
US20070005006A1 (en) | 2005-06-15 | 2007-01-04 | Rosenfeld Paul E | Methods and devices for removal of toxic compounds from breast milk |
US20070010760A1 (en) * | 2005-06-15 | 2007-01-11 | Paul Rosenfeld | Binding and removal of contaminants and other chemical agents through novel enhanced carbon-based filtration methods, processes and products |
WO2008035888A1 (en) * | 2006-09-21 | 2008-03-27 | Se Hee Kim | Filter device of nursing bottle containing powdered milk, filter device using magnet and feeder |
WO2009009188A2 (en) * | 2007-04-19 | 2009-01-15 | 3M Innovative Properties Company | Uses of water-dispersible silica nanoparticles for attaching biomolecules |
Non-Patent Citations (8)
Title |
---|
BERLIN CM; BRIGGS GG: "Drugs and chemicals in human milk", SEMIN FETAL NEONATAL MED, vol. 10, 2005, pages 149 - 159 |
BOGEN DL; DAVIES ED; BARNHART WC; LUCERO CA; MOSS DR: "What do mothers think about concurrent breast-feeding and smoking?", AMBUL PEDIATR., vol. 8, no. 3, 2008, pages 200 - 204 |
HILL HJ: "Food additives and contaminants and their contribution to the human cancer load", EUR J CANCER PREV, vol. 2, 1993, pages 291 - 295 |
ITO S; LEE A: "Drug excretion into breast milk-Overview", ADVANCED DRUG DELIVERY REVIEWS, vol. 55, no. 5, 2003, pages 617 - 627 |
MENNELLA JA; YOURSHAW LM; MORGAN LK: "Breastfeeding and smoking: short-term effects on infant feeding and sleep", PEDIATRICS, vol. 120, no. 3, 2007, pages 497 - 502 |
POLLOCK 1: "Hyperactivity and food additives", BIBL NUTR DIETA, vol. 48, 1991, pages 81 - 89 |
SAGRAVES R: "Drugs in Breast Milk: a Scientific Explanation", J PEDIATR HEALTH CARE, vol. 11, no. 5, 1997, pages 230 - 235 |
SENYUVA H Z ET AL: "Immunoaffinity column clean-up techniques in food analysis: A review", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 878, no. 2, 15 January 2010 (2010-01-15), pages 115 - 132, XP026851455, ISSN: 1570-0232, [retrieved on 20090528] * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11771769B2 (en) | 2017-11-10 | 2023-10-03 | Cocoon Biotech Inc. | Ocular applications of silk-based products |
WO2019126308A1 (en) * | 2017-12-19 | 2019-06-27 | Stc.Unm | Lipase inhibitors to prevent rancidity in expressed human milk during storage |
US20200323225A1 (en) * | 2017-12-19 | 2020-10-15 | Stc.Unm | Lipase inhibitors to prevent rancidity in expressed human milk during storage |
CN109126887A (en) * | 2018-09-10 | 2019-01-04 | 湖南科技大学 | A kind of preparation method of polyurethane composite photocatalysis membrane |
CN110835458A (en) * | 2019-11-15 | 2020-02-25 | 湖南绿斯达生物科技有限公司 | Biodegradable material with antibacterial effect and high strength, and preparation and application thereof |
CN110835458B (en) * | 2019-11-15 | 2021-12-24 | 湖南绿斯达生物科技有限公司 | Biodegradable material with antibacterial effect and high strength, and preparation and application thereof |
CN110975834A (en) * | 2019-12-19 | 2020-04-10 | 浙江工业大学 | Ultra-light floatable material and preparation method and application thereof |
CN110975834B (en) * | 2019-12-19 | 2022-03-25 | 浙江工业大学 | Ultra-light floatable material and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017213597A1 (en) | Breast milk purification method and device for carrying out the same | |
CN106255520A (en) | Use the method that high flow rate removes antibacterial from blood | |
CA2481711C (en) | Method and device for selective separation of a compound from a body fluid | |
AU2011370959B2 (en) | Target-directed, magnetically enhanced system for detoxification of patients | |
JP5876476B2 (en) | Improvement of bioactive compounds from wastewater | |
JPH11502450A (en) | Oral administration of beneficial substances | |
CN110269867A (en) | Composition for biofluid purification | |
US20140255409A1 (en) | Method for extracorporeal elimination of one or more components from blood | |
CN105339067A (en) | Blood filtration system containing mannose coated substrate | |
Alkan et al. | Selective removal of the autoantibodies from rheumatoid arthritis patient plasma using protein A carrying affinity cryogels | |
WO2018051312A1 (en) | In-line filter for protein/peptide drug administration | |
CN103028376A (en) | Blood purifying adsorbent used for removing blood toxin and preparation method | |
Yu | Adsorbents in blood purification: from lab search to clinical therapy | |
Woźniak-Budych | Polymeric membranes for biomedical applications | |
WO2014011111A1 (en) | A device for removal of medical substances or other unwanted substances from urine or medical liquids, and a catheter bag | |
US9011684B2 (en) | Fluid concentrator with removable cartridge | |
CN203139198U (en) | Simple blood purifier | |
US20190262824A1 (en) | Devices and Methods to Reduce Contamination of Fluid Collected Through a Conduit By Absorbent Diversion | |
AU2008201015B2 (en) | Improved separation | |
WO2008035888A1 (en) | Filter device of nursing bottle containing powdered milk, filter device using magnet and feeder | |
RU2090186C1 (en) | Sorbent for extraction of antibodies raised to insulin from biological fluids and a method of its preparing | |
CN116139096A (en) | Adsorption device based on DNA composite gel microsphere and preparation method and application thereof | |
WO2024073717A1 (en) | Adsorption technology | |
JP3150682B2 (en) | Medical sterilization filter and medical injection circuit | |
CN201160978Y (en) | Improved safety blood transfusion bag |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16735737 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16735737 Country of ref document: EP Kind code of ref document: A1 |